What does Caris Life Sciences do?
Caris Life Sciences, Inc. is an Irving, Texas-based precision-oncology diagnostics and data company. Its CAI shares trade primarily on Nasdaq and, since June 17, 2026, also on NYSE Texas. Caris analyzes tissue, blood, pathology images, and clinical outcomes to support therapy selection, cancer-origin identification, recurrence assessment, early detection, and clinical-trial matching. Its official platform combines whole-genome, whole-exome, and whole-transcriptome sequencing with protein analysis and machine learning.
Where does Caris sit in the healthcare value chain?
Caris connects oncology care, laboratory diagnostics, software interpretation, and biopharma research. Physicians order tests, Caris analyzes samples, payers reimburse covered testing, and drug developers purchase research or data services. Each profile can enlarge the dataset, supporting new algorithms and diagnostics.
| Identity dimension | Caris position | Why it matters |
|---|---|---|
| Reporting structure | One operating and reportable segment | Investors must analyze revenue streams and products rather than rely on formal segment profit disclosure. |
| Core customers | Oncologists, hospitals, academic centers, payers, and biopharma companies | Adoption depends on both clinical utility and reimbursement economics. |
| Primary market | United States | U.S. reimbursement policy and laboratory regulation dominate near-term economics. |
| Strategic identity | Diagnostics plus clinico-genomic data platform | The company is broader than a test vendor but still earns most revenue from clinical profiling. |
Why does the company matter?
Oncology increasingly requires DNA, RNA, protein, tumor-context, and outcomes information rather than a single-gene result. Caris attempts to unify those inputs. Its importance depends on whether comprehensive profiling produces evidence that physicians, regulators, and payers accept as clinically useful and economically justified.
How does Caris Life Sciences make money?
Caris discloses two revenue streams. Molecular profiling is the engine: the company analyzes a specimen, delivers a report, and recognizes revenue on delivery. Commercial insurers, Medicare, institutions, or patients may pay. Because collections can differ from estimates, revenue reflects both test volume and expected reimbursement by payer and product mix. Caris explains the model in its 2025 Form 10-K.
| Revenue stream | Customer and pricing logic | Q1 2026 revenue | Key driver |
|---|---|---|---|
| Molecular profiling services | Clinical tests ordered by physicians or institutions; collections depend on payer coverage, contracts, coding, and patient mix. | $210.8M | Case volume plus average selling price and reimbursement. |
| Pharma R&D services | Contract research, profiling, trial support, strategic data, and related services for biopharma partners. | $5.4M | Project timing, milestones, and customer study activity. |
| Total | Clinical diagnostics dominate; research services broaden the platform and monetize data. | $216.2M | Profiling adoption and reimbursement quality. |
Which revenue source carries the business?
How does one test create multiple forms of value?
Caris earns current cash from tests but reinvests in evidence, data, algorithms, sales capacity, and new products. Analysis should separate reported profiling revenue from the optionality in early detection, recurrence prediction, MRD, and drug discovery.
Which tests, data assets, and customer groups matter most?
Caris’s products span the cancer-care continuum but differ in maturity. MI Profile is the established tissue therapy-selection platform. Caris Assure extends profiling into blood and uses matched white blood cells to separate tumor signals from clonal hematopoiesis and incidental germline findings. Official Caris Assure information cites more than 23,000 genes and a six-to-nine-day average turnaround.
| Platform or product | Clinical or commercial role | Current analytical importance |
|---|---|---|
| MI Profile / MI Cancer Seek | Tissue-based therapy selection using broad molecular profiling and protein testing. | Largest mature volume base and a major reimbursement driver. |
| Caris Assure | Blood-based therapy selection with whole-exome and whole-transcriptome analysis. | Fastest visible case-volume expansion in Q1 2026. |
| Caris Detect | Commercial multi-cancer early-detection blood test using ultra-deep WGS, WTS, and AI. | Large addressable opportunity, but adoption and validation remain emerging. |
| MI Clarity and GPSai | AI models for breast-cancer recurrence risk and tissue-of-origin prediction. | Evidence that Caris can turn its dataset into software-like clinical outputs. |
| CODEai / Strategic Data | Linked molecular, treatment, and outcomes data for researchers and biopharma. | Supports data monetization, trials, biomarker discovery, and model development. |
What do case volumes reveal?
How concentrated is the commercial footprint?
The GPSai tool compares a tumor signature with 90 cancer categories. The logic is cumulative: each profile has clinical value, while the expanding database becomes harder for a smaller laboratory to reproduce.
What did Caris's latest reported quarter show?
As of July 22, 2026, the newest completed package covers the quarter ended March 31, 2026. Revenue, gross margin, operating profit, and cash generation improved sharply. The Q1 2026 release attributes growth mainly to profiling volume and higher average selling prices.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Molecular profiling revenue | $210.8M | $114.1M | An 84.8% increase; the principal growth engine. |
| Pharma R&D revenue | $5.4M | $6.8M | Down 21.4%, reflecting project timing rather than core clinical volume. |
| Gross profit | $141.3M | $57.1M | Pricing, payer mix, and scale lifted gross economics. |
| Net loss | $0.5M | $102.6M | Near break-even, although interest expense still exceeded interest income. |
| Operating cash flow | $32.9M | $(31.3)M | Collections and working capital converted reported growth into cash. |
Why did margin improve so much?
Q1 2026 operating expenses were $136.1M, up 18%—far slower than revenue. R&D was $31.3M, selling and marketing $45.0M, and G&A $59.7M, producing an approximately 2.4% operating margin. Net loss persisted because $12.8M of interest expense exceeded $6.8M of interest income. See the Q1 2026 Form 10-Q.
How does the quarter compare with the annual growth path?
How did Caris build its precision-oncology position?
Caris’s history is a sequence of capability layers: laboratory infrastructure, broader sequencing, linked outcomes, AI interpretation, blood testing, regulated products, and public capital. Each layer expanded clinical utility or proprietary data available for future products.
Which turning points still shape the company today?
-
2008Caris was founded around a patient-centered precision-medicine vision. That origin still supports a strategy of comprehensive, rather than narrowly targeted, molecular analysis.
-
2015The Precision Oncology Alliance was established, creating an academic and clinical network that supports evidence generation, adoption, and access to high-quality outcomes data.
-
2019-2020Whole-transcriptome and whole-exome sequencing, GPSai, and CODEai broadened the platform from laboratory testing into AI-enabled interpretation and real-world clinico-genomic research.
-
2022Strategic data licensing and Caris Discovery extended monetization toward biopharma research, target identification, and drug-development services.
-
2024-2025Caris Assure expanded blood-based therapy selection; MI Cancer Seek received FDA premarket approval in late 2024 and launched in January 2025, improving the tissue platform’s reimbursement and product mix.
-
June 2025The company completed its initial public offering. The IPO was priced at $21 per share, adding capital for commercialization, research, and balance-sheet flexibility.
-
April-July 2026ChromoSeq, MI Clarity, and Caris Detect broadened the company into hematologic profiling, computational-pathology recurrence risk, and multi-cancer early detection.
The pattern is vertical integration across data generation, interpretation, evidence, and commercialization. It may accelerate learning, but raises fixed costs and requires simultaneous execution in diagnostics, software, evidence, reimbursement, and biopharma services.
What gives Caris a competitive advantage?
Caris’s strongest potential moat is a data flywheel of consistently generated molecular profiles linked to treatment and outcomes. Through March 31, 2026, it reported 1.07M total profiles, 790,000 matched profiles, 677,000-plus whole-exome profiles, and 728,000-plus whole-transcriptome profiles. Its CODEai platform covers matched information for more than 484,000 patients. Standardized scale can strengthen model training, biomarker discovery, and product development.
Which resources look hardest to reproduce?
Network depth adds another barrier. At year-end 2025, the Precision Oncology Alliance had 99 members, including more than 45 NCI-designated centers, and Caris reported over 6,000 ordering physicians. These relationships support validation, workflow integration, and trials. Patents help, but clinical performance and payer acceptance determine the practical moat.
Where is the moat less certain?
Caris is hardest to imitate where data scale, assay breadth, clinical relationships, and reimbursement reinforce one another. Protection weakens when customers multi-source testing or rivals achieve similar outcomes with narrower, cheaper approaches.
Who competes with Caris across tissue, blood, and data?
Caris competes across tissue profiling, liquid biopsy, MRD, early detection, computational pathology, data licensing, and biopharma services. Its 10-K names Foundation Medicine, Tempus, Guardant Health, Natera, GRAIL, Freenome, Exact Sciences, Personalis, and others; the relevant rival varies by use case.
| Competitive arena | Representative rivals named by Caris | Caris positioning | Main pressure point |
|---|---|---|---|
| Tissue profiling | Foundation Medicine, Tempus, academic centers | Broad WES, WTS, protein analysis, and integrated interpretation. | Clinical evidence, turnaround, payer contracts, and workflow penetration. |
| Blood therapy selection | Guardant, Tempus, Foundation Medicine | Whole-blood approach designed to subtract clonal hematopoiesis. | Sensitivity, specificity, reimbursement, and physician familiarity. |
| Early detection | GRAIL, Freenome, Guardant, Exact Sciences, Delfi | Ultra-deep whole-genome and whole-transcriptome strategy. | Large trials, regulatory pathway, cost, false positives, and screening adoption. |
| MRD and monitoring | Natera, Guardant, Personalis, BillionToOne, Quest, Adaptive | Tumor-naive, bespoke-free development approach. | Validation, recurrence sensitivity, and time to clinical utility. |
| Data and biopharma | Tempus, Foundation Medicine, Guardant, Natera | Large matched multi-omic and outcomes dataset. | Data completeness, exclusivity, analytics usability, and customer budgets. |
Where does Caris sit strategically?
Advantage must be judged by use case. A focused rival may win through lower cost, stronger indication-specific evidence, better payer contracts, or an established workflow. Rivalry and payer power are high; barriers are strongest where scale, validation, regulation, and reimbursement must all be achieved together.
How strong are Caris's cash flow and balance sheet?
Caris entered 2026 with far greater flexibility after the IPO. FY2025 produced $812.0M of revenue, $45.1M of operating income, $83.2M of operating cash flow, and $66.9M of free cash flow, reversing FY2024 free cash flow of negative $253.6M. Q1 2026 extended the improvement, but one quarter is not a normalized cash profile.
How did Q1 revenue convert into cash?
Free cash flow equals operating cash flow minus property-and-equipment purchases; Q1 2026 margin was about 10.4%. Working capital helped as receivables fell $21.6M and payables rose $16.4M. Researchers should separate structural margin gains from collection timing.
What does liquidity permit?
| Financial item | Amount and period | Analytical implication |
|---|---|---|
| Cash and equivalents | $819.9M at March 31, 2026 | Provides launch, evidence-generation, and commercial capacity. |
| Short-term securities | $2.3M at March 31, 2026 | Adds modest liquid resources beyond cash. |
| Term-loan principal | $400.0M before the April 2026 refinancing | Gross leverage remains material, but cash exceeded principal debt. |
| Accumulated deficit | Approximately $2.5B at March 31, 2026 | The recent profit inflection follows a long period of funded losses. |
| FY2025 IPO proceeds | $528.5M, net of underwriting discounts and commissions | Public capital transformed liquidity and reduced financing constraints. |
After quarter-end, Caris refinanced its $400M facility at a lower cost and added access to strategic capital. It also announced an up to $100M repurchase authorization. Repurchases may offset dilution, but clinical validation and commercialization may offer higher returns if execution succeeds.
Who owns Caris stock, and why does founder control matter?
Caris common stock carries one vote per share, but ownership is concentrated. The 2026 proxy reports founder, chairman, and CEO David Dean Halbert at 125.0M shares, or 43.9%, on March 31, 2026. Officers and directors as a group held 145.9M shares, or 50.0%; that group includes Halbert, so the figures overlap.
| Holder or group | Beneficial ownership | Share of class | Why it matters |
|---|---|---|---|
| David Dean Halbert | 125.0M shares | 43.9% | Founder influence is substantial across strategy, leadership, and shareholder votes. |
| Executive officers and directors as a group | 145.9M shares | 50.0% | Insider economics are closely tied to long-term equity value, while minority influence is limited. |
| FMR LLC | 30.6M shares | 10.8% | A large institutional holder can influence governance engagement and market liquidity. |
| Sixth Street affiliates | 19.4M shares | 6.9% | Reflects continued ownership by a major pre-public capital provider. |
| J.H. Whitney affiliates | 18.3M shares | 6.5% | Another meaningful legacy investor with economic exposure. |
How concentrated is beneficial ownership?
The 2026 proxy also shows dilution potential from equity awards and options. Valuation should use a forward diluted share estimate. Governance analysis should test alignment, board oversight, incentives, and capital-allocation treatment of minority holders.
What opportunities, risks, and valuation drivers should researchers monitor?
Caris is expanding from profiling into a broader cancer-information platform. The opportunity is to convert sequencing and outcomes data into new products without weakening core economics. The July 1, 2026 Detect launch describes ultra-deep WGS and WTS supported by more than one million cases and 50 billion-plus molecular markers.
Which growth signals deserve attention?
What could weaken the story?
A DCF should not extrapolate Q1 growth indefinitely. Forecast mature therapy selection separately from emerging products; model volume, reimbursement, normalized working capital, stock compensation, dilution, and sustainable margins. Upside requires more use cases from the same infrastructure; downside arises if launch costs outpace reimbursed demand.
What is the key takeaway from Caris Life Sciences analysis?
Caris combines a scaling diagnostics business, a large multimodal oncology dataset, and an AI-enabled product pipeline. FY2025 and Q1 2026 showed that reimbursement, case growth, and operating leverage can produce positive operating income and free cash flow. Cash supports investment; founder ownership supports continuity.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.